Illinois Municipal Retirement Fund Has $1.88 Million Stock Holdings in Amgen Inc. $AMGN

Illinois Municipal Retirement Fund lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 25.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,648 shares of the medical research company’s stock after selling 2,225 shares during the period. Illinois Municipal Retirement Fund’s holdings in Amgen were worth $1,876,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. TAGStone Capital Inc. lifted its stake in Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after acquiring an additional 32 shares in the last quarter. Wealth Quarterback LLC grew its stake in shares of Amgen by 1.6% in the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after acquiring an additional 34 shares in the last quarter. DDFG Inc raised its holdings in shares of Amgen by 1.1% in the third quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock valued at $850,000 after purchasing an additional 34 shares during the last quarter. LS Investment Advisors LLC lifted its position in shares of Amgen by 4.1% during the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock valued at $250,000 after purchasing an additional 35 shares in the last quarter. Finally, Crown Wealth Group LLC lifted its position in shares of Amgen by 4.0% during the third quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 35 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.69% of the stock is owned by insiders.

Amgen Trading Up 0.8%

Shares of AMGN opened at $369.19 on Tuesday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $385.12. The business has a 50-day moving average of $338.43 and a 200 day moving average of $314.29. The firm has a market cap of $198.80 billion, a P/E ratio of 25.94, a price-to-earnings-growth ratio of 3.78 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the business earned $5.31 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of recent analyst reports. Daiwa Securities Group upped their price objective on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Mizuho upped their price objective on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $354.04.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.